94 results
424B3
RGBP
Regen BioPharma Inc
29 Apr 24
Prospectus supplement
4:08pm
attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
IN WITNESS
8-K
EX-10.1
RGBP
Regen BioPharma Inc
29 Apr 24
Entry into a Material Definitive Agreement
4:07pm
and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.
IN WITNESS WHEREOF, the parties have
424B3
RGBP
Regen BioPharma Inc
20 Nov 23
Prospectus supplement
9:38am
credit equal to 50% of clinical investigation expenses as well as exemptions from certain fees.
The Company believes that this application … States federal tax credit equal to 50% of clinical investigation expenses as well as exemptions from certain fees.
The Company believes
424B3
RGBP
Regen BioPharma Inc
2 Oct 23
Prospectus supplement
1:42pm
% of clinical investigation expenses as well as exemptions from certain fees.
The Company believes that this application of HemaXellerate qualifies for Orphan
8-K
EX-10.3
ku206m4wh1dmjpoum
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.1
a986o2vl
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.4
xbmk5rr70 3i6
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
8-K
EX-10.2
4ycne8 705q
18 Sep 23
Entry into a Material Definitive Agreement
4:02pm
424B3
6mw eiy3r
15 May 23
Prospectus supplement
10:25am